Universal Initial Approval Criteria
Covered when ALL applicable criteria are met:
ALL of the following
Requested product is Prolia, Bildyos, Boncresa, Bosaya, Conexxence (denosumab-bnht), Enoby, Jubbonti, Ospomyv (denosumab-dssb), Osvyrti, Ponlimsi (denosumab-adet), or Stoboclo (denosumab-bmwo).
Bildi yos and Enoby are preferred denosumab products; the member has a contraindication, intolerance, or failure of Bildyos and Enoby.
Member is at least 18 years of age.
Member supplements with 1,000 mg of calcium and at least 400 IU of vitamin D daily.
Member does not have an FDA-labeled contraindication to the requested agent, including hypocalcemia or known hypersensitivity.
For members with advanced kidney disease (eGFR <30 mL/min/1.73 m², including dialysis-dependent members), CKD-mineral and bone disorder is evaluated with intact parathyroid hormone, serum calcium, 25-hydroxy vitamin D, and 1,25-dihydroxy vitamin D before denosumab treatment decisions.
Pregnancy is ruled out before administration in biological females of child-bearing potential.
Requested therapy will not be used in combination with another denosumab product, a bisphosphonate, romosozumab, or a parathyroid hormone analog or related peptide.
Osteoporosis in Men and Women
Covered when ALL applicable criteria are met:
ALL of the following
For a biological female, member is post-menopausal.
Member is at high risk for fracture.
ONE of the following
Documented osteoporosis with a DXA T-score ≤ -2.5 at the lumbar spine, femoral neck, total hip, or forearm at the 33% (one-third) radius site.
History of fragility fracture of the hip or spine, regardless of T-score.
Glucocorticoid-Induced Osteoporosis
Covered when ALL applicable criteria are met:
ALL of the following
Member is initiating or continuing systemic glucocorticoid therapy at a daily dosage equivalent to ≥2.5 mg of prednisone and is expected to remain on glucocorticoid therapy for at least 3 months.
Member is at increased risk for fracture.
ONE of the following
Documented treatment failure or ineffective response to a minimum 12-month trial of an oral or intravenous bisphosphonate, such as alendronate, risedronate, ibandronate, or zoledronic acid.
Documented contraindication or intolerance to both oral and intravenous bisphosphonates.
Prostate Cancer — Increase Bone Mass
Covered when ALL applicable criteria are met:
ALL of the following
Member is receiving androgen deprivation therapy.
Member is at high risk for fracture.
Breast Cancer — Increase Bone Mass
Covered when the following criterion is met:
Member is receiving adjuvant aromatase inhibitor therapy for breast cancer.
Systemic Mastocytosis
Covered when ALL applicable criteria are met:
ALL of the following
Member has osteopenia or osteoporosis and coexisting bone pain.
ONE of the following
Denosumab is being used as second-line therapy because the member is not responding to bisphosphonate therapy.
Member is not a candidate for bisphosphonate therapy because of renal insufficiency.
Indication-Specific Dosing
The applicable dose and schedule must correspond to the requested indication:
ONE applicable dosing pathway
Osteoporosis or systemic mastocytosis: 60 billable units every 6 months.
Giant cell tumor of bone or hypercalcemia of malignancy: loading dose of 120 billable units on days 1, 8, 15, and 29, followed by maintenance dosing of 120 billable units every 4 weeks.
Bone metastases from solid tumors or multiple myeloma: 120 billable units every 4 weeks.
Universal Criteria for Xgeva and Other Oncology Indications
Covered when ALL applicable criteria are met:
ALL of the following
Member will receive calcium and vitamin D as necessary to treat or prevent hypocalcemia; this requirement does not apply when treatment is for hypercalcemia of malignancy.
Member does not have an FDA-labeled contraindication to the requested agent, including hypocalcemia or known clinically significant hypersensitivity to Xgeva or denosumab products.
Requested therapy will not be used in combination with another denosumab product, a bisphosphonate, romosozumab, or a parathyroid hormone analog or related peptide.
Multiple Myeloma or Bone Metastases from Solid Tumors
Covered when ALL applicable criteria are met:
ALL of the following
Member is at least 18 years of age.
ONE of the following
Member has tried zoledronic acid for at least 3 months and had an inadequate response, contraindication, or intolerance.
Member has metastatic breast cancer, metastatic castration-resistant prostate cancer, or metastatic lung cancer, including small-cell or non-small-cell lung cancer.
Giant Cell Tumor of Bone
Covered when ALL applicable criteria are met:
ALL of the following
Member is an adult or is at least 12 years of age and skeletally mature.
ONE of the following
Disease is unresectable or surgical resection is likely to result in severe morbidity.
ALL of the following
Disease is localized, recurrent, or metastatic.
ONE of the following
Denosumab is used as a single agent.
Hypercalcemia of Malignancy
Covered when ALL applicable criteria are met:
ALL of the following
Member is at least 18 years of age.
Member has a diagnosis of cancer (malignancy).
ONE of the following
Refractory hypercalcemia of malignancy, defined as albumin-corrected calcium >12.5 mg/dL (3.1 mmol/L) despite a minimum 7-day trial of intravenous bisphosphonate therapy, such as ibandronate or zoledronic acid.
Documented contraindication or intolerance to intravenous bisphosphonates, such as ibandronate or zoledronic acid.
Renewal Criteria
Renewal requires ALL applicable criteria:
ALL of the following
Member continues to meet universal and relevant indication-specific criteria identified in the initial approval criteria, including applicable concomitant therapy requirements, performance status, and other clinical requirements; prerequisite therapy requirements do not need to be repeated.
Member has no unacceptable toxicity from the drug, including severe symptomatic hypocalcemia, osteonecrosis of the jaw, atypical femoral fracture, dermatologic adverse reaction, severe infection, severe hypersensitivity or anaphylaxis, or musculoskeletal pain.
Beneficial response is demonstrated for the applicable indication
Systemic mastocytosis: improvement or resolution of bone pain compared with pretreatment baseline.
Systemic mastocytosis: absence of fractures.
Osteoporosis Duration Management
For osteoporosis in men and women, after 5 years of treatment, ALL of the following are required:
ALL of the following
Member will have a repeat DXA performed after 5 years of treatment.
Member's fracture risk has been reassessed.
If disease risk is low to moderate, therapy will be changed to an oral or intravenous bisphosphonate unless the member has a contraindication or intolerance to both dosage forms.
Glucocorticoid-Induced Osteoporosis Duration Management
For glucocorticoid-induced osteoporosis, after 2 years of treatment, ALL of the following are required:
ALL of the following
Member will have a repeat DXA performed after 2 years of treatment.
Member's fracture risk has been reassessed.
If disease risk is low to moderate, therapy will be changed to an oral or intravenous bisphosphonate unless the member has a contraindication or intolerance to both dosage forms.
Coverage is not provided when the requested agent has an FDA-labeled contraindication, including hypocalcemia or known hypersensitivity. Hypocalcemia must be corrected before treatment when applicable. For oncology indications, calcium and vitamin D should be provided as necessary to treat or prevent hypocalcemia, except when the indication is hypercalcemia of malignancy.
Coverage may be denied when required age, diagnosis, fracture-risk, prior-therapy, laboratory-monitoring, pregnancy-screening, response, or toxicity criteria are not documented or are not met.
Members with advanced kidney disease, including dialysis-dependent members, require evaluation for CKD-mineral and bone disorder with intact parathyroid hormone, serum calcium, 25-hydroxy vitamin D, and 1,25-dihydroxy vitamin D before treatment decisions.
Pregnancy must be ruled out before administration in biological females of child-bearing potential.
Denosumab must not be used in combination with another denosumab product, bisphosphonates, romosozumab, or parathyroid hormone analogs or related peptides. Requests involving prohibited combination therapy are not covered.